Drug uptake in CD-1 mouse cerebellum at 0.07 mCi, iv after 90 mins in presence of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]-thiophene 5,5-dioxide
Drug uptake in CD-1 mouse other brain regions at 0.07 mCi, iv after 90 mins in presence of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]-thiophene 5,5-dioxide
Drug uptake in CD-1 mouse superior and inferior colliculus at 0.07 mCi, iv after 90 mins in presence of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]-thiophene 5,5-dioxide
Drug uptake in CD-1 mouse hippocampus at 0.07 mCi, iv after 90 mins in presence of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)dibenzo[b,d]-thiophene 5,5-dioxide
Toxicity in CD-1 mouse assessed as change in locomotor activity at 0.07 mCi, iv after 90 mins in presence of 7-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-2-fluorodibenzo[b,d]-thiophene 5,5-Dioxide
Toxicity in CD-1 mouse assessed as change in behavioral activity at 0.07 mCi, iv after 90 mins in presence of 7-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-2-fluorodibenzo[b,d]-thiophene 5,5-Dioxide
Drug uptake in CD-1 mouse cerebellum at 0.07 mCi, iv after 90 mins in presence of 3-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-6-fluorodibenzo[b,d]thiophene 5,5-Dioxide
Drug uptake in CD-1 mouse cerebellum at 0.07 mCi, iv after 90 mins in presence of 7-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-2-fluorodibenzo[b,d]-thiophene 5,5-Dioxide
Ratio of clearance in CD-1 mouse cerebellum to clearance in CD-1 mouse other brain tissues at 70 uCi, iv followed by compound washout after 90 mins by gamma-counting analysis